Q32 Bio director granted 9,810 stock options

Q32 Bio Inc. director Sven Ante Lundberg received a grant of stock options covering 9,810 shares of common stock.

Rhea-AI Filing Summary

Q32 Bio Inc. director Sven Ante Lundberg received a grant of stock options covering 9,810 shares of common stock. The options have an exercise price of $12.64 per share and expire on June 11, 2036. This is a compensation-related award, not an open-market purchase.

All 9,810 underlying shares will vest and become exercisable in full on the earlier of June 12, 2027 or the date of Q32 Bio’s next annual meeting of stockholders, provided Lundberg continues serving as a director through that vesting date.

Insider Trade Summary

Grant/Award: 9,810 shares

Grant/Award 1 txn

Insider Lundberg Sven Ante

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	9,810	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 9,810 contracts (Direct)

Footnotes (1)

1. F1. The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

Key Figures

Option grant size: 9,810 options Exercise price: $12.64 per share Expiration date: June 11, 2036 +2 more

5 metrics

Option grant size 9,810 options Stock Option (Right to Buy) granted to director

Exercise price $12.64 per share Exercise price for underlying common stock

Expiration date June 11, 2036 Option expiration for this grant

Shares underlying options 9,810 shares Common stock underlying the stock options

Post-transaction derivative holdings 9,810 options Total shares following transaction for this award

Key Terms

Stock Option (Right to Buy), exercise price, vesting, annual meeting of stockholders, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 12.6400"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"shares underlying this option shall vest and become exercisable in full"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of stockholders financial

"the date of the Issuer's next annual meeting of stockholders"

grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Q32 Bio (QTTB) director Sven Ante Lundberg report on this Form 4?

Sven Ante Lundberg reported receiving a grant of stock options for 9,810 shares of Q32 Bio common stock. These options are a compensation-related award, not a market trade, and give him the right to buy shares at a fixed exercise price in the future.

How many Q32 Bio (QTTB) shares are covered by Lundberg’s new stock options?

The new stock option grant covers 9,810 shares of Q32 Bio common stock. This entire amount is shown as held following the transaction, reflecting a newly awarded derivative position rather than a purchase or sale of existing common shares in the market.

What is the exercise price and expiration date of Lundberg’s Q32 Bio options?

The options have an exercise price of $12.64 per share and expire on June 11, 2036. This means Lundberg can choose to buy up to 9,810 shares at $12.64 any time after vesting and before the June 2036 expiration date.

When do Sven Ante Lundberg’s Q32 Bio (QTTB) options vest?

All 9,810 options vest in full on the earlier of June 12, 2027 or the date of Q32 Bio’s next annual meeting of stockholders. Vesting requires Lundberg’s continued service as a director through the applicable vesting date specified in the grant terms.

Is Lundberg’s Q32 Bio Form 4 transaction a stock purchase or sale?

The filing shows a grant of stock options classified as an acquisition under code A, not an open-market purchase or sale. No common shares were bought or sold; instead, Lundberg received options as compensation that may be exercised for shares later.

How many Q32 Bio derivative securities does Lundberg hold after this option grant?

After the transaction, Lundberg holds 9,810 stock options linked to Q32 Bio common stock under this award. The total_shares_following_transaction field lists 9,810, matching the newly granted options associated with this specific compensation grant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/16/2026 - 04:30 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lundberg Sven Ante

(Last) (First) (Middle)

Q32 BIO INC.

830 WINTER STREET

(Street)

WALTHAM MASSACHUSETTS 02451

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Q32 Bio Inc. [ QTTB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$12.64	06/12/2026		A		9,810		(1)	06/11/2036	Common Stock	9,810	$0	9,810	D

Explanation of Responses:

1. The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

	/s/ Eric Bell, Attorney-in-Fact	06/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)